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RESEARCH NOTE
Clinicopathologic features of invasive 
metaplastic and micropapillary breast 
carcinoma: comparison with invasive ductal 
carcinoma of breast
Atif Ali Hashmi1, Saher Aijaz2, Raeesa Mahboob1, Saadia Mehmood Khan1, Muhammad Irfan3, Narisa Iftikhar1, 
Mariam Nisar1, Maham Siddiqui4, Muhammad Muzzammil Edhi6, Naveen Faridi5 and Amir Khan7* 
Abstract 
Objectives: The aim of this study was to determine the frequency of metaplastic breast carcinoma and invasive 
micropapillary carcinoma in our population and also to compare the clinico-pathologic features of metaplastic breast 
carcinoma and invasive micropapillary carcinoma with invasive ductal carcinoma, not otherwise specified (IDC, NOS).
Results: 86.9% of the cases were identified as ductal carcinoma, NOS, while 2.2% were metaplastic and 0.76% cases 
were micropapillary carcinoma. Metaplastic carcinomas were found to be of higher grade as compared to IDC, NOS 
as 81% of metaplastic carcinoma were grade III compared to 35% IDC, NOS. 79% of metaplastic carcinoma were ER 
negative and 86% were PR negative, respectively as compared to ductal carcinoma NOS, which were 40% ER nega-
tive and 54% were PR. Similarly, 86.7% micropapillary cancers were ER positive and 73.3% were PR positive. Moreover, 
66.7% micropapillary carcinoma showed nodal metastasis and 77.8% showed lymphovascular invasion, which was 
significantly higher than that of IDC, NOS micropapillary and metaplastic carcinomas accounts for less than 2 and 1% 
of the breast cancer burden in our population and highly correlates with poor prognosis parameters therefore, require 
more intensive management in our population.
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Introduction
Due to heterogeneous nature of the breast cancer, under-
standing of potentially aggressive cancers helps in design-
ing tailored therapeutic interventions as it assists in 
comprehending the prognosis of the disease. Metaplastic 
breast carcinomas (MBC) and invasive micropapillary 
breast carcinomas (IMBC) are two aggressive pheno-
typic variants of breast cancers with a low prevalence rate 
amongst the general population. Although these variants 
are relatively rare but pose significant challenge in terms 
of breast cancer treatment. Majority of the special sub-
types of breast carcinoma including mucinous, tubular, 
cribriform etc. are more indolent in behavior than con-
ventional ductal carcinoma, not otherwise specified, and 
confers relatively better prognosis and favorable out-
comes [1–3]. Invasive micropapillary carcinoma is rec-
ognized by tubulo-alveolar formation, which is visible 
in empty spaces with fragile pseudopapillary structures 
devoid of fibro-vascular core scattered across the mem-
brane [4]. This micropapillary differentiation is visible as 
tight clusters of tumor cells present in cleft like retraction 
spaces resembling lymphatics [5]. Clinical significance 
of micropapillary differentiation relies on high inci-
dence of nodal metastasis [6]. Metaplastic carcinomas 
are a diverse group of tumors showing divergent differ-
entiation towards squamous, spindle cell or mesenchy-
mal. These tumors are found to be negative for hormone 
receptors and Her2neu and therefore exhibit a basal like 
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breast cancer profile [7, 8]. As a consequence of systemic 
metastasis, they are regarded as one of the most aggres-
sive breast tumors [9]. Epithelial to mesenchymal transi-
tion in these subtypes of breast carcinomas are proposed 
to be associated with the tendency of the tumor cells to 
acquire properties of stem cells [10]. Since these subtypes 
of breast cancers are less responsive to conventional hor-
monal and chemotherapeutic interventions, we aimed to 
evaluate the frequency of metaplastic breast carcinoma 
and invasive micropapillary carcinoma in our popula-
tion with regard to clinico-pathologic features of invasive 
ductal carcinoma, not otherwise specified. Moreover, in 
the era of personalized therapy, knowledge of histologic 
and prognostic parameters of individual types of can-
cers is extremely important as these features may differ 
in different populations. Therefore, evaluating prognostic 
features of micropapillary and metaplastic breast cancer 
in this study will be helpful in individualizing treatment 
strategies in locoregional population.
Main text
Methods
We reviewed 1951 cases of breast carcinoma treated 
at Liaquat National hospital from January 2008 till 
December 2014. The specimens include trucut biop-
sies, breast conservation surgeries and modified radi-
cal mastectomies. All the slides of these cases were 
retrieved and reviewed by two experienced patholo-
gists. Micropapillary differentiation was defined as 
tumor nests present in cleft like spaces resembling lym-
phatic spaces. Micropapillary carcinomas were defined 
as tumors with > 90% micropapillary differentiation 
(Fig.  1). Metaplastic carcinomas were categorized as 
tumors showing spindle cell, squamous or mesenchy-
mal differentiation (osseous, chondroid or matrix pro-
ducing stroma) as shown in Fig.  1. Histopathologic 
characteristics recorded include tumor type, size, grade 
and lymph node status along with degree of necrosis, 
lymphocytic reaction and fibrosis. One representative 
Fig. 1 a Microscopic sections of Micropapillary carcinoma, ×40 showing tumor cells in cleft like retraction spaces. b Microscopic sections of 
Micropapillary carcinoma, ×200 showing reverse polarization of tumor cells. c Microscopic sections of Metaplastic carcinoma showing spindled 
tumor cells with myxoid matrix producing stroma, ×40 magnification. d Microscopic sections of Metaplastic carcinoma, ×200 magnification, 
showing tumor cells floating in chondromyxoid stroma
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section is selected for IHC studies including ER, PR, 
her2neu and ki67 by DAKO envision method. Follow-
ing antibodies are used.
1. FLEX Monoclonal Rabbit Anti-human Estrogen 
receptor alpha, clone EP1, ready to use, purchased 
from DAKO (code IR084).
2. FLEX Monoclonal Mouse Anti-human Progester-
one receptor, clone PgR 636, ready to use, purchased 
from DAKO (code IR068).
3. Polyclonal Rabbit Anti-human c-erbB-2 oncoprotein, 
purchased from DAKO (code A0485).
4. FLEX Monoclonal Mouse Anti-human, Ki67 Anti-
gen, Clone MIB-1, Ready to use, purchased from 
DAKO (code IR626).
Immunohistochemistry was performed using DAKO 
envision kit according to manufacturers recommenda-
tions. Normal breast tissue was used as positive controls 
for ER, PR and as negative control for Her2neu. Known 
case of her2neu amplified breast cancer was used as posi-
tive control for Her2neu. For ki67 benign reactive lymph 
node was used as positive control.
More than 1% nuclear staining for ER/PR was consid-
ered positive expression.
HER2neu were scored based on the intensity and per-
centage of positive cells on a scale of 0 to 3 + according to 
ASCO/CAP guidelines [11, 12]. Cases with intermediate 
(2+) expression of Her2neu underwent subsequent FISH 
testing for Her2neu gene amplification. FISH testing was 
performed using FDA approved Path Vysion Her2 DNA 
Probe kit according and reported according to CAP 
guidelines.
Ki-67 immunoreactivity was recorded as continuous 
variables, based on the proportion of positive tumor cells 
(0–100%). At least 1000 cells were evaluated before cal-
culating an average estimate. If hot spots were present, 
then they are included in the estimation. Ki67 index was 
further categorized into four groups, < 14%, 15–24%, 
25–44%, > 45%.
Statistical package for social sciences (SPSS 21) was 
used for data compilation and analysis. Mean and stand-
ard deviation were calculated for quantitative variables. 
Frequency and percentage were calculated of qualitative 
variables. Chi square was applied to see association. T 
test was applied to compare difference in means among 
groups by considering P-value ≤ 0.05 as significant.
Results
The study involved 1951 cases of primary breast carci-
noma, out of which 1695 (86.9%) cases were ductal carci-
noma, NOS, while 43 (2.2%) and 15 (0.76%) cases were of 
metaplastic and micropapillary carcinoma, respectively 
and thus included in the study. Table 1 shows the com-
parison of metaplastic carcinoma with ductal carcinoma, 
NOS.
Metaplastic carcinomas were found to be of higher 
grade as compared to ductal carcinoma NOS (81% of 
metaplastic carcinoma were grade III compared to 35% 
ductal carcinoma, NOS). Similarly, metaplastic carci-
noma differs with ductal carcinoma NOS in terms of ER/
PR positivity. 79 and 86% of metaplastic carcinoma were 
ER and PR negative, respectively as compared to ductal 
carcinoma NOS (40 and 54% were ER and PR negative, 
respectively). No significant difference was noted in 
respect to T-stage and N-stage of metaplastic carcinoma 
as compared to ductal carcinoma NOS. Lack of insitu 
component was noted in more than half of cases of meta-
plastic carcinoma which differs significantly from ductal 
carcinoma NOS. Majority of metaplastic carcinomas 
were triple negative (67.4%) compared to ductal carci-
noma NOS, most of which are luminal B (44%).
Table 2 shows the comparison of various clinico-path-
ologic features of micropapillary carcinoma with ductal 
carcinoma NOS. No significant association was noted 
except for ER and PR positivity, where micropapillary 
cancers were noted to have more frequent positivity of 
these biomarkers (micropapillary cancers were 86.7 and 
73.3% ER and PR positive compared to 60 and 46% in 
ductal carcinoma NOS).
Although micropapillary cancers were found to be 
associated with 66.7% frequency of nodal metastasis, 
however to significant difference was noted when com-
pared to ductal carcinoma NOS. Furthermore, mean 
ki67 index of micropapillary carcinoma was 35.8 and 26% 
were of grade III. Her2neu positivity was noted in 60% of 
cases. Higher frequency of lymphovascular invasion was 
noted in micropapillary carcinoma (77.8%) compared to 
ductal carcinoma NOS (24.8%). 86.7% of micropapillary 
carcinoma were luminal B compared to 44% of ductal 
carcinoma, NOS.
Discussion
In the present study we found a low frequency of meta-
plastic and micropapillary carcinoma, however these 
rare types were found to be associated with adverse 
prognostic parameters. Metaplastic carcinomas were 
noted to have higher grade and lower expression of 
hormonal receptors, while micropapillary carcinoma 
showed higher frequency of lymphovascular invasion. 
Clinico-pathologic evaluation of tumors is principal to 
predict the outcome and life expectancy of the patients. 
On account of the recognition of ductal carcinomas and 
previously classified as not otherwise specified carcino-
mas, today the rate of treatment failure has been largely 
reduced [13]. An antecedent study conducted in the 
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year 2014, revealed that the incidence of tumors dem-
onstrating ductal morphology was as high as 83% in the 
population [15]. Furthermore, a meaningful number of 
tumors exhibited metaplastic as well as medullary char-
acteristics [14, 15]. On the grounds of our previous find-
ings; in this study we focused on the clinico-pathologic 
and histopathologic features of the invasive micropapil-
lary breast carcinoma and the invasive metaplastic car-
cinoma. Alongside studying these clinico-pathologic 
features of invasive metaplastic and micropapillary breast 
carcinoma, we also compared the two subtypes with the 
invasive ductal carcinoma, not otherwise specified of the 
breast to expand our knowledge and understanding.
According to Weigelt et  al. only 25% of carcinomas 
diagnosed in laboratory settings are histologically ‘spe-
cial type’ and further classified into 17 pathological 
types, while the rest are invasive ductal carcinoma not 
otherwise specified [16]. In congruence with the previ-
ous studies, we observed that ductal carcinoma, not oth-
erwise specified were the most prevalent type of breast 
cancer in our population, constituting 84% of all breast 
cancers diagnosed in the laboratory, while only a meagre 
number of cases of metaplastic (2.2%) and micropapil-
lary (0.76%) carcinomas were notable. The incidence of 
metaplastic carcinoma was found to be less than 1% by 
previous studies [17–20], however, in the present study, 
Table 1 Association of  clinico-pathologic parameters 
of  metaplastic breast cancer subtype with  Ductal 
carcinoma, NOS
n (%) P-value
Metaplastic Ductal, NOS Total
Age (years)ab 49.21 ± 12.92 50.54 ± 12.48 – 0.49
Age group (n = 1738)
 ≤ 30 3 (3.3) 89 (5.3) 92 (5.3) 0.767
 31–50 21 (48.8) 822 (48.8) 843 (48.5)
 51–70 16 (37.2) 692 (40.8) 708 (40.7)
 > 70 3 (7) 92 (5.4) 95 (5.5)
Tumor grade (n = 1738)
 Grade 1 3 (7) 160 (9.4) 163 (9.4) ≤ 0.05
 Grade 2 5 (11.6) 945 (55.8) 950 (54.7)
 Grade 3 35 (81.4) 590 (34.8) 625 (36)
Ki67  valueab 40.05 ± 22.67 35.92 ± 23.33 – 0.252
Ki67 index category (n = 1738)
 < 15 4 (9.3) 373 (22) 377 (21.7) 0.203
 15–24 11 (25.6) 311 (18.3) 322 (18.5)
 25–44 12 (27.9) 406 (24) 418 (24.1)
 > 44 16 (37.2) 605 (35.7) 621 (35.7)
Size of  tumorab 36.77 ± 15.31 36.11 ± 14.84 – 0.825
Tumor stage (n = 660)
 T1 4 (15.4) 83 (13.1) 87 (13.2) 0.695
 T2 17 (65.4) 454 (71.6) 471 (71.4)
 T3 5 (19.2) 97 (15.3) 102 (15.5)
Nodal status (n = 660)
 Positive 12 (46.2) 318 (50.2) 330 (50) 0.689
 Negative 14 (53.8) 316 (48.8) 330 (50)
N stage (n = 660)
 N0 14 (53.8) 320 (50.5) 334 (50.6) 0.431
 N1 5 (19.2) 130 (20.5) 135 (20.5)
 N2 1 (3.8) 85 (13.4) 86 (13)
 N3 6 (23.1) 99 (15.6) 105 (15.9)
Laterality (n = 1738)
 Left 19 (44.2) 865 (51) 884 (50.9) 0.375
 Right 24 (55.8) 830 (49) 854 (49.1)
ER (n = 1738)
 Positive 9 (20.9) 1019 (60.1) 1028 (59.1) ≤ 0.05
 Negative 34 (79.1) 676 (39.9) 710 (40.9)
PR (n = 1738)
 Positive 6 (14) 779 (46) 785 (45.2) ≤ 0.05
 Negative 37 (86) 916 (54) 953 (54.8)
Her2neu (n = 1738)
 Positive 9 (20.9) 742 (43.8) 751 (43.2) ≤ 0.05
 Negative 34 (79.1) 953 (56.2) 987 (56.8)
Lymphocytic infiltration (n = 660)
 Absent 10 (38.5) 364 (57.4) 374 (56.7) 0.132
 Moderate 13 (50) 210 (33.1) 223 (33.8)
 Severe 3 (11.5) 60 (9.5) 63 (9.5)
Table 1 (continued)
n (%) P-value
Metaplastic Ductal, NOS Total
Insitu component (n = 659)
 Present 11 (42.3) 432 (68.2) 443 (67.2) ≤ 0.05
 Absent 15 (57.7) 201 (31.8) 216 (32.8)
Lymphovascular invasion (n = 660)
 Present 8 (30.8) 157 (24.8) 165 (25) 0.488
 Absent 18 (69.2) 477 (75.2) 495 (75)
Dermal lymphatic invasion (n = 660)
 Present 0 (0) 78 (12.3) 78 (11.8) 0.061
 Absent 26 (100) 556 (87.7) 582 (88.2)
Pagetoid spread (n = 660)
 Present 0 (0) 14 (2.2) 14 (2.1) 1.000
 Absent 26 (100) 620 (97.8) 646 (97.9)
Molecular subtypes(n = 1738)
 Triple negative 29 (67.4) 298 (17.6) 327 (18.8) ≤ 0.05
 HER 2 5 (11.6) 363 (21.4) 368 (21.2)
 Luminal A 1 (2.3) 287 (16.9) 288 (16.6)
 Luminal B 8 (18.6) 747 (44.1) 755 (43.4)
Chi Square applied
a Mean ± SD
b Independent t-Test
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we observed that the incidence of MBC has increased 
significantly (2.2% in the present study).
In addition, a marked variation in tumor grade and 
frequency of ER and PR genes was noticed between the 
metaplastic and ductal carcinoma not otherwise speci-
fied, where metaplastic carcinomas were characterized 
by high tumor grade as compared to IDC NOS. Since 
tumor grade is one of the predominant histopathologic 
feature that predicts the outcome of disease [21–23]. It 
can be said that metaplastic carcinoma is more aggres-
sive in behavior than IDC NOS. Moreover, the ER and 
PR positivity was significantly low in our study. A previ-
ous study also demonstrated that the percentage of ER, 
PR and HER-2 positivity was less than 10% in metaplas-
tic carcinoma [18]. Our analysis also showed congru-
ence with these findings as HER-2 positivity was found 
to be 21% in metaplastic carcinomas and 44% in invasive 
ductal carcinoma, not otherwise specified.
Furthermore, a significant number of metaplastic car-
cinoma were found to be triple negative (84%), unlike 
DC, NOS which were predominantly luminal B type. 
The findings of our study are consistent with other stud-
ies which demonstrated that triple negative characteristic 
was the predominant molecular subtype in metaplastic 
carcinoma [18, 25]. Due to triple negative characteristic 
of metaplastic carcinomas, they are regarded as more 
aggressive type of cancers which are often less-respon-
sive to endocrine therapy [24].
Table 2 Association of  clinico-pathologic parameters 
of  micropapillary breast cancer subtype with  ductal 
carcinoma, NOS
n (%) P-value
Micropapillary Ductal, NOS Total
Age (years)ab 48.20 ± 14.02 50.54 ± 12.48 – 0.47
Age group (n = 1710)
 ≤ 30 2 (13.3) 89 (5.3) 91 (5.3) 0.323
 31–50 7 (46.7) 822 (48.5) 829 (48.5)
 51–70 5 (33.3) 692 (40.8) 697 (40.8)
 > 70 1 (6.7) 92 (5.4) 93 (5.4)
Tumor grade (n = 1710)
 Grade 1 0 (0) 160 (9.4) 160 (9.4) 0.386
 Grade 2 11 (73.3) 945 (55.8) 956 (55.9)
 Grade 3 4 (26.7) 590 (34.8) 594 (34.7)
Ki67  valueab 35.80 ± 22.94 35.92 ± 23.33 – 0.984
Ki67 index category (n = 1710)
 < 15 2 (13.3) 373 (22) 375 (21.9) 0.582
 15–24 4 (26.7) 311 (18.3) 315 (18.4)
 25–44 5 (33.3) 406 (24) 411 (24)
 > 44 4 (26.7) 605 (35.7) 609 (35.6)
Size of  tumorab 33.11 ± 14.77 36.11 ± 14.84 – 0.547
Tumor stage (n = 643)
 T1 1 (11.1) 83 (13.1) 84 (13.1) 1.000
 T2 7 (77.8) 454 (71.6) 461 (71.7)
 T3 1 (11.1) 97 (15.3) 98 (15.2)
Nodal status (n = 643)
 Positive 6 (66.7) 318 (50.2) 324 (50.4) 0.505
 Negative 3 (33.3) 316 (49.8) 319 (49.6)
N stage (n = 643)
 N0 4 (44.4) 320 (50.5) 324 (50.4) 0.417
 N1 2 (22.2) 130 (20.5) 132 (20.5)
 N2 0 (0) 85 (13.4) 85 (13.2)
 N3 3 (33.3) 99 (15.6) 102 (15.9)
Laterality (n = 1710)
 Left 9 (60) 865 (51) 874 (51.1) 0.489
 Right 6 (40) 830 (49) 836 (48.9)
ER (n = 1710)
 Positive 13 (86.7) 1019 (60.1) 1032 (60.4) ≤ 0.05
 Negative 2 (13.3) 676 (39.9) 678 (39.6)
PR (n = 1710)
 Positive 11 (73.3) 779 (46) 790 (46.2) ≤ 0.05
 Negative 4 (26.7) 916 (54) 920 (53.8)
Her2neu (n = 1710)
 Positive 9 (60) 742 (43.8) 751 (43.9) 0.207
 Negative 6 (40) 953 (56.2) 959 (56.1)
Lymphocytic infiltration (n = 643)
 Absent 3 (33.3) 364 (57.4) 367 (57.1) 0.241
 Moderate 5 (55.6) 210 (33.1) 215 (33.4)
 Severe 1 (9.5) 60 (9.5) 61 (9.5)
Table 2 (continued)
n (%) P-value
Micropapillary Ductal, NOS Total
Insitu component (n = 642)
 Present 2 (22.2) 432 (68.2) 434 (67.6) ≤ 0.05
 Absent 7 (77.8) 201 (31.8) 208 (32.4)
Lymphovascular invasion (n = 643)
 Present 7 (77.8) 157 (24.8) 164 (25.5) ≤ 0.05
 Absent 2 (22.2) 477 (75.2) 479 (74.5)
Dermal lymphatic invasion (n = 643)
 Present 2 (2.5) 78 (12.3) 80 (12.4) 0.311
 Absent 7 (77.8) 556 (87.7) 563 (87.6)
Pagetoid spread (n = 643)
 Present 0 (0) 14 (2.2) 14 (2.2) 1.000
 Absent 9 (100) 620 (97.8) 629 (97.8)
Molecular subtypes (n = 1710)
 Triple negative 1 (6.7) 298 (17.6) 299 (17.5) ≤ 0.05
 HER 2 1 (6.7) 363 (21.4) 364 (21.3)
 Luminal A 0 (0) 287 (16.9) 287 (16.8))
 Luminal B 13 (86.7) 747 (44.1) 760 (44.4)
Chi Square applied
a Mean ± SD
b Independent t-Test
Page 6 of 7Hashmi et al. BMC Res Notes  (2018) 11:531 
On the other hand, the incidence of invasive micropap-
illary carcinoma was reported to be less than 2% (rang-
ing from 0.7 to 3%) of all invasive breast carcinomas [24, 
25]. In our study, we found that less than 1% of the cases 
of breast cancers accounted for invasive micropapillary 
carcinoma. The clinico-pathologic findings of micropap-
illary carcinoma in our study revealed a high ER and PR 
positivity ratio as compared with invasive ductal carci-
noma, not otherwise specified. ER positivity was visible 
in 87% of the cases of IMPC, while only 60% of IDC, 
NOS showed ER positivity. In another study, ER positiv-
ity ranged from 19.4 to 90.6% in invasive micropapillary 
carcinomas [26]. One of the study also indicated that 
high PR positivity in invasive micropapillary carcinomas 
is advantageous in terms of survival and attributable to 
increased life expectancy in these patients. Therefore, 
these characteristics suggest good prognosis in patients 
with MIBC as compared to IDC, NOS since high posi-
tivity of ER and PR correlates with good prognosis and 
tumor outcomes [27, 28] Notwithstanding with these 
correlations, the IMPC is characterized by poor prog-
nosis and aggressive behavior due to high propensity for 
nodal metastasis and lymphovascular invasion [27, 28], 
despite of high PR and ER positivity. The findings of our 
study reaffirm high incidence of lymphovascular inva-
sion, as noted in 78% of micropapillary carcinomas com-
pared to only 25% ductal carcinoma NOS.
In conclusion, invasive micropapillary carcinoma and 
invasive metaplastic carcinoma are rare breast cancer 
subtypes accounting for less than 2 and 1% of the breast 
cancer burden in our population. Both of the types cor-
relate with adverse prognosis and poor outcomes. Owing 
to high tumor grade and loss of hormonal receptor 
expression in metaplastic carcinomas, they are believed 
to be less responsive to conventional therapies. Similarly, 
frequent lymphovascular invasion in micropapillary car-
cinoma correlates with aggressive nature.
We recommend larger-scale, population level studies to 
find the prevalence of the two rare subtypes of the breast 
cancer in our population since the results of our study 
cannot be extrapolated to the whole population as it 
dealt with a single-facility data. A multi-center study can 
determine the true prevalence of these rare subtypes of 
breast cancer in our population and then by knowing the 
adverse prognostic features of these tumors, therapeutic 
protocols can be developed for locoregional population.
Limitations
Lack of clinical follow up to determine recurrence and 
disease free survival was the major limitation of our 
study. Moreover, molecular studies like oncotype Dx 
was not performed on these tumors to determine their 
molecular adverse prognostic features.
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